RxDoctor Payments Data

Whitney Miller, NP

Family · Logan, WVNPI 1760979777

Payments from drug & device makers

$576in general payments, 2019–2025

Across 23 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$262
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$68
  • Novo Nordisk$48
  • Gilead$44
  • Organon$34
  • Otsuka America Pharmaceutical, Inc.$27
  • plus $93 from 5 others

What the payments were for

  • Food & beverage$576100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$576 in reported general payments places this provider in the 55th percentile of 1,507 family providers in West Virginia.

See all family providers in West Virginia

Medicare billing

Part B allowed, 2024
$540
Medicare patients
12
Services billed
24

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl36$40,872
OzempicSemaglutide14$20,136
JardianceEmpagliflozin23$16,748
EliquisApixaban11$7,540
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,449
Lantus SolostarInsulin Glargine,hum.Rec.Anlog27$5,780
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl39$2,933
Albuterol Sulfate HfaAlbuterol Sulfate77$2,006
Buspirone Hcl161$1,439
Aripiprazole85$1,323
Testosterone14$998
Duloxetine Hcl86$821
Quetiapine Fumarate111$787
Prazosin Hcl61$778
Venlafaxine Hcl ErVenlafaxine Hcl72$626

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$262$40,87236 claims
Novo NordiskOzempic$48$20,13614 claims
Lilly USA, LLCOlanzapine$19$42751 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,507 family providers in West Virginia.

Other family in Logan

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →